In running through the chemokine pathways for CCR5 blockade I have not seen a case where a more effective blockade nullifies effect. The main MOA for leronlimab in NASH is as an anti-inflammatory, just like in Covid. If it's anti-inflammatory effects were neutralized or reversed at higher doses than we should have seen little to no improvement for the first two weeks and then increasing improvement as the amount of receptor occupancy declined.